Summary of "5. Breast Lump - SURGERY AUDIO Case presentation for Final MBBS by Ghanashyam Vaidya"
Case overview
- Patient: Shanti Bai, 50-year-old woman.
- Presentation: Lump in the right breast noticed 3 months earlier, gradually increasing in size.
- Obstetric/gynecologic history: Multiparous (4 children), last delivery 15 years ago, breastfed all children. No recent lactation, no oral contraceptive use, no prior breast surgery.
- Family history: No known family history of breast cancer (speaker notes discussed higher risk if positive).
- Clinical impression (presenter): Malignant tumor of the right breast, most likely carcinoma — Manchester clinical stage III.
Key teaching points
Differential diagnoses for a breast lump
- Carcinoma of the breast (higher suspicion in older/post‑menopausal patients).
- Fibroadenoma (more common in younger women; soft, mobile).
- Fibrocystic disease / simple cysts / galactocele (fluid‑filled, may be tender, related to reproductive events).
- Fat necrosis, lipoma.
- Abscess / mastitis (tender, inflammatory signs).
- Sarcoma (rare).
- Filariasis / elephantiasis (rare, regionally specific cause of massive enlargement).
- Paget’s disease of the nipple (nipple eczema, usually unilateral with underlying malignancy).
Note: Fibroadenomas and cysts are more typical in younger patients; malignancy is more likely in older/post‑menopausal patients and when lumps are hard, fixed, or associated with skin/nipple changes.
Important risk and protective factors
- Increased risk:
- Positive family history (mother/sister) — approximately ~5× population risk.
- BRCA‑1 mutation — high risk and often more aggressive disease.
- Nulliparity and late first pregnancy.
- Protective:
- Breastfeeding.
- Other factors (e.g., hormonal therapies) were mentioned but were not present in this patient.
Clinical breast examination — stepwise method and interpretation
Inspection
- Examine sitting and then leaning forward; compare both breasts for symmetry.
- Look for skin changes (dimpling, tethering, ulceration), visible lumps, and nipple position/level.
- Distinguish nipple displacement (measurable change relative to landmarks) from nipple deviation (change in direction the nipple points).
Palpation
- Systematically palpate all quadrants using the flat of the hand; record size in three dimensions when possible.
- Note number, consistency (soft, firm, hard), mobility, and tenderness.
- Palpate with fingers aligned with muscle fibers and at right angles to assess fixation to underlying muscle.
- Pinch test: attempt to lift skin over the lump — inability to lift suggests skin infiltration.
- Test mobility relative to pectoralis muscle by having the patient tense muscles or press against a wall.
Nipple evaluation
- Compress from periphery to center to elicit discharge; document character (clear/serous, milky, bloody — bloody can suggest malignancy).
- Look for nipple retraction — distinguish congenital from acquired (acquired suggests infiltration/fibrosis).
- Differentiate Paget’s disease (unilateral nipple eczema/erosion often with underlying carcinoma) from ordinary eczema (often bilateral and responsive to topical therapy).
Regional lymph nodes
- Examine axillary groups: central, pectoral (anterior), subscapular (posterior), lateral; also check supraclavicular and infraclavicular nodes.
- Use specific palpation techniques (e.g., push high into axilla for central nodes; examine anterior axillary fold for pectoral nodes).
- Note size, number, tenderness, fixation. In this case a single mobile ~3 cm axillary node was palpable.
Skin signs and their significance
- Peau d’orange (orange‑peel edema): due to dermal lymphatic obstruction — strongly suggestive of carcinoma.
- Ulceration: may indicate locally advanced or fungating tumor.
- Eczematous nipple changes: consider Paget’s disease if unilateral and associated with underlying carcinoma.
Clinical features suspicious for carcinoma
- Age > 40–50 years and a progressively enlarging lump.
- Hard consistency, irregular margins.
- Fixation to skin or muscle, peau d’orange, nipple retraction or displacement.
- Bloody nipple discharge.
- Palpable regional lymphadenopathy.
Investigations recommended
Baseline blood tests
- Complete hemogram.
- Blood sugar (and HbA1c).
- Renal function (BUN/creatinine).
- Liver function tests.
- HIV testing as per local protocol.
Imaging
- Mammography: detect masses, microcalcifications, architectural distortion; useful for screening and evaluating multicentric disease.
- Breast ultrasound: useful for dense breasts and to characterize cystic versus solid lesions.
- Chest X‑ray: baseline for pulmonary metastasis; further imaging (CT chest, bone scan, liver ultrasound/CT) if metastasis suspected.
Tissue diagnosis
- FNAC (fine needle aspiration cytology) or core needle biopsy — core biopsy preferred for histology and receptor testing (ER/PR/HER2).
Staging investigations
- Directed by clinical stage and symptoms (bone scan, CT/MRI as indicated).
Clinical staging (Manchester classification)
- Stage I: Tumor confined to breast; no palpable nodes; no skin involvement.
- Stage II: Breast tumor (size criteria variable) with mobile ipsilateral nodes.
- Stage III: Skin involvement (edema, ulceration), chest wall fixation/infiltration, or matted/fixed ipsilateral nodes — locally advanced disease.
- Stage IV: Distant metastasis (visceral or bony).
Treatment principles and options
Early localized disease (breast conservation feasible)
- Breast-conserving surgery (wide local excision / lumpectomy) with clear margins (1 cm margin mentioned) plus sentinel lymph node biopsy.
- Mandatory postoperative radiotherapy to the breast.
- Sentinel node biopsy intraoperatively (frozen section if available); if sentinel node positive, perform level I/II axillary clearance.
Modified radical mastectomy (MRM)
- Indications: larger tumors not suitable for conservation, multicentric disease, patient preference, some stage II/III tumors.
- Removes breast tissue, skin including nipple‑areolar complex, and axillary lymph nodes (typically levels I–II); pectoralis major preserved.
Simple (total) mastectomy
- Removes breast tissue and skin/nipple but does not include axillary dissection — used in selected situations (e.g., prophylactic surgery or when nodes addressed separately).
Locally advanced (stage III) disease
- Consider neoadjuvant (primary systemic) chemotherapy to downstage and attempt resectability.
- If downstaged and resectable, proceed to surgery (often MRM) followed by adjuvant therapy.
- If unresectable or after maximal therapy, focus on palliation with radiotherapy/chemotherapy as appropriate.
Adjuvant systemic therapy
- Chemotherapy: based on stage, histology, and node status.
- Hormonal therapy: for ER/PR‑positive tumors.
- Anti‑HER2 therapy (trastuzumab): for HER2‑positive tumors — typical duration ~1 year.
Radiotherapy
- Mandatory after breast‑conserving surgery.
- Consider post‑mastectomy radiotherapy in high‑risk situations (large tumors, positive margins, multiple positive nodes).
Multidisciplinary follow‑up
- Coordinated care among surgery, medical oncology, radiation oncology, and pathology is essential.
Other practical points emphasized
- Record lump size in three dimensions.
- Differentiate inflammatory carcinoma (rapid onset inflammatory signs) from infectious mastitis.
- Recognize that benign entities (fat necrosis, chronic abscess) can mimic malignancy clinically.
- In advanced disease, assess for systemic spread (lungs, liver, bones) both clinically and with targeted imaging.
Presenter’s recommended management for this case
Given a lump >2 cm with a palpable (mobile) axillary node and clinical skin involvement consistent with locally advanced disease, the presenter recommended modified radical mastectomy plus adjuvant radiotherapy, chemotherapy, and hormonal therapy as indicated by receptor status. If the tumor is initially unresectable, neoadjuvant chemotherapy to attempt downstaging before surgery was recommended.
Speakers and sources referenced
- Dr. Ghanshyam (Ghanshyam) Vaidya — presenter (Lecturer, Karnataka Health Institute; alumnus of Seth G.S. Medical College and Hospital, Mumbai).
- Case patient name: Shanti Bai.
- Institutions/terms: Karnataka Health Institute; Seth G.S. Medical College and Hospital, Mumbai.
- Clinical references mentioned: Manchester clinical staging; BRCA‑1; sentinel lymph node biopsy; modified radical mastectomy; Paget’s disease; trastuzumab (anti‑HER2 monoclonal therapy).
Note: Subtitles in the recorded talk were auto‑generated and contained transcription errors; this summary captures the clinical teaching, examination technique, differential diagnosis, investigations, and treatment principles as presented.
Category
Educational
Share this summary
Is the summary off?
If you think the summary is inaccurate, you can reprocess it with the latest model.
Preparing reprocess...